The Filing Desk

Pacira BioSciences vs Ultragenyx Pharmaceutical

Pacira BioSciences PCRX · Ultragenyx Pharmaceutical RARE · Pharmaceuticals

Pacira BioSciences reported revenue of $726 million in fiscal 2025, about the same as Ultragenyx Pharmaceutical's $673 million in fiscal 2025. Pacira BioSciences' revenue grew 3.6% in its latest year, and Ultragenyx Pharmaceutical's grew 20.2%. Pacira BioSciences had an operating margin of 2.6%, against -79.5% at Ultragenyx Pharmaceutical. Free cash flow was $137 million at Pacira BioSciences and −$472 million at Ultragenyx Pharmaceutical.

Side by side

Pacira BioSciencesUltragenyx Pharmaceutical
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$726M$673M
Revenue growth3.6%20.2%
Revenue growth a year, last 5 years11.1%20.0%
Gross margin79.4%—
Operating margin2.6%−79.5%
Net margin1.0%−85.4%
Free cash flow$137M−$472M
Free cash flow margin18.8%−70.1%
Return on capital1.1%—
Net debt to EBITDA1.2x—
Dividends and buybacks$148M$0M
Change in diluted share count−2.6%8.9%
Last close$36.46$16.08
P/E at the last close39.2×—
Insider trades, last 12 monthssold $2.3 millionsold $3.7 million
Piotroski F-score9 of 9—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Pacira BioSciencesUltragenyx Pharmaceutical
Operating margin
Percent of revenue
Pacira BioSciencesUltragenyx Pharmaceutical
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Pacira BioSciencesUltragenyx Pharmaceutical

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Pacira BioSciences and Ultragenyx Pharmaceutical pages.